Recipients of T cell-depleted allogeneic bone marrow transplants have increased risks of relapse and graft rejection. The addition of donor T cells to the TCD allograft will decrease the risk of graft rejection but will increase the risk of graft-versus-host disease (GVHD). Relapse of leukemia or lymphoma following allogeneic bone marrow transplantation can be successfully treated with post-transplant infusions of donor lymphocytes. A relatively small number of donor T cells can have a profound anti-tumor effect and facilitate engraftment, but has an unpredictable potential for severe GVHD. An alternative to using viable immunocompetent donor immune cells to facilitate engraftment and to treat relapsed patients are donor lymphocytes that have been treated to limit their ability to proliferate and cause GVHD. The effectiveness of allogeneic bone marrow transplantation in treating leukemia is related to both the conditioning regimen and the graft-versus-leukemia (GVL) effect. [1] [2] [3] [4] Relapsed leukemia after allogeneic bone marrow transplantation can be successfully treated with post-transplant infusions of donor lymphocytes. Complete responses to donor lymphocyte therapy are seen in approximately 70% of CML patients, 20% of AML patients, and less than 15% of patients with relapsed ALL.
of irradiated allogeneic T cells. Irradiated allogeneic lymphocytes that retain short-term allo-specific cytotoxicity and lack the potential for clonal expansion in vivo can be considered as a novel form of immunotherapy with defined pharmacokinetics. Bone Marrow Transplantation (2000) 25, Suppl. 2, S20-S24. Keywords: allogeneic bone marrow transplantation; immunotherapy; irradiated lymphocytes; relapse
The effectiveness of allogeneic bone marrow transplantation in treating leukemia is related to both the conditioning regimen and the graft-versus-leukemia (GVL) effect. [1] [2] [3] [4] Relapsed leukemia after allogeneic bone marrow transplantation can be successfully treated with post-transplant infusions of donor lymphocytes. Complete responses to donor lymphocyte therapy are seen in approximately 70% of CML patients, 20% of AML patients, and less than 15% of patients with relapsed ALL. 5 A relatively small inoculum of donor T cells can have a profound anti-leukemic effect, but with an unpredictable potential for severe graft-versushost disease. Reported series of donor lymphocyte therapy described incidences of grade 2-4 GVHD from 15% 6 to 60% 5 and a treatment-related mortality rate of 12% overall. 6 Our own experience with donor lymphocyte infusions (DLI) for relapsed patients at Emory University has shown a 30% long-term survival among 15 treated patients, and a 27% incidence of fatal GVHD. 7 An alternative to using viable immunocompetent donor immune cells to treat relapsed patients are donor lymphocytes that have been treated to limit their ability to proliferate and cause GVHD. Doses of more than 5 Gy ionizing radiation limit the proliferative capacity of T cells. T cells treated with irradiation retain cytotoxic activity against tumor cells and host immune cells. 8, 9 A human T cell line (TALL-104), irradiated to 20 Gy, has been effective in eliminating clonogenic human leukemic cells when co-cultures of irradiated T cells and leukemia cells were infused into human bone xenografts in immunodeficient SCID-hu mice. 10 There are limited reports on the use of irradiated allogeneic lymphocytes in animal models of bone marrow transplantation. 11, 12 The addition of irradiated (15 Gy) donor lymphocytes alone did not prevent graft rejection when they were administered to rabbit recipients of allogeneic bone marrow transplantation. A combination of cyclosporine immuno-suppression, TCD allogeneic BM, irradiated autologous BM and irradiated allogeneic buffy coat cells increased the rate of engraftment to 80%. 11 The Seattle group found that infusions of irradiated (20 Gy) donor lymphocytes to DLA mismatched bone marrow transplants did not prevent fatal graft failure. 12 In the same dog model, gamma irradiation (20 Gy) of whole blood products transfused prior to DLA-mismatched allogeneic bone marrow transplantation in dogs prevented sensitization to alloantigens in recipients but did not induce allo-specific tolerance. 13 We have tested the hypothesis that allogeneic donor T cells treated with low-dose irradiation to inhibit their proliferative capacity are able to facilitate engraftment and mediate an anti-leukemia effect in a mouse model of bone marrow transplantation. Based upon encouraging pre-clinical results we have initiated phase I trials of multiple infusions of irradiated allogeneic donor lymphocytes in patients. Preliminary data from these trials indicate that multiple infusions of irradiated allogeneic lymphocytes are safe and have anti-tumor activity in vivo. These studies provide the basis for using irradiated donor lymphocytes as a new strategy in allogeneic stem cell transplantation. ) background were obtained from Dr Miriam Lieberman, Stanford University. Mice were given acidified sterile water and maintained in Micro isolator cages (Lab Products, Maywood, NJ, USA). Bone marrow cells and spleen cells were harvested from donor mice as previously described. 14 
Materials and methods

Animal husbandry and donor cell preparation
Bone marrow transplantation
Recipient mice were exposed to 10 Gy or 11 Gy of radiation from a 137 Cs source, delivered in two equal fractions, 3 h apart, at a dose rate of 1.24 Gy/min. Splenocytes were irradiated using a single fraction from the same 137 Cs source. Mice received intravenous administration of bone marrow and spleen cells into the retro-orbital sinus.
Analysis of hematopoietic engraftment and GVHD among transplant recipients
Peripheral blood at day +30 and day +112 was analyzed for host and donor leukocytes and T cells using monoclonal antibodies and FACS as previously described.
14 All transplant recipients were evaluated for the presence of clinical GVHD as manifested by weight loss, alopecia and/or ruffled fur, diarrhea, and a 'hunched over' appearance. Necropsy was performed following euthanasia of moribund mice and of mice at predetermined time points.
Statistical analyses
Survival differences between different groups were calculated with the Cox test comparing different survival curves
Bone Marrow Transplantation in a pair-wise fashion. Differences between mean values were compared using the Student's t-test. Differences between the fraction of animals surviving at day 30 were determined using the Fisher's test.
Results
Preclinical studies of irradiated T cells in a mouse BMT model
In preliminary studies we determined that irradiation of mouse T cells to 7.5 Gy inhibited their proliferative capacity in vitro and in vivo and prevented GVHD in parent → F1 mouse BMT.
14 Multiple infusions of irradiated allogeneic donor lymphocytes in the peri-transplant period had graft-enhancing activity without resulting in GVHD. ).
14 Recipients of an equal number of non-irradiated donor splenocytes uniformly died of hyper-acute GVHD.
Recipients of irradiated allogeneic splenocytes and allogeneic bone marrow had stable donor-derived hematopoiesis without a significant contribution of irradiated donor cells to the T cell compartment. Among recipients of allogeneic BM and irradiated splenocytes, 9/11 mice engrafted with donor cells with a median of 100% of all blood cells and 100% of peripheral blood T cells derived from the donor bone marrow (Table 1 ). Significant numbers of blood T cells derived from the infusions of irradiated allogeneic splenocytes (Ͻ10% of T cells) were seen only in two of 11 mice that received 75 × 10 6 irradiated splenocytes, at frequencies of 10% and 33%. The remaining 9/11 mice had less than 5% of peripheral blood T cells derived from the irradiated splenocyte infusion. Removing T cells from the allogeneic splenocytes by MACS prior to irradiation largely eliminated their graft facilitating activity (Table 1) , indicating that the active element in the irradiated donor splenocytes were CD3 + T cells. 14 
Survival of human T cells after exposure to ionizing radiation
We determined the effect of graded doses of ionizing radiation in the dose range between 2.5 Gy and 20 Gy on the survival of human T cells in culture. Human PBMC cells were irradiated and then cultured in the presence of OKT3 and IL2, conditions which might model in vivo environment of allo reactive cells in a HLA-mismatched recipient. Similar conditions have been previously shown to prevent apoptotic death of irradiated T cells. 15 The absolute numbers of T cells and NK cells in each culture were determined by periodically removing aliquots, counting viable cells and the percentage of cells expressing CD3 and/or CD56. In these culture conditions, growth of T cells predominated over that of NK cells, and exposure to 7.5 Gy or more irradiation effectively eliminated viable T cells and NK B10.BR mice received 11 Gy irradiation on day −2 and were transplanted with 1 × 10 6 bone marrow cells or 1 × 10 6 T cell-depleted (TCD) bone marrow cells from C57.BL6 mice, or a combination of bone marrow and 75 × 10 6 irradiated (7.5 Gy) C57.BL6 splenocytes or bone marrow and 60 × 10 6 T celldepleted irradiated (7.5 Gy) C57.BL6 splenocytes. The C57.BL6 donor mice were all CD45.1 + bone marrow and spleen donors varied according to their expression of Thy 1.1 (spleen) or Thy 1.2 (bone marrow). The median percentages of peripheral blood cells that were donor derived (CD45.1+), and the percentage of blood T cells that were derived from donor bone marrow, donor spleen, or were of host origin were determined at day +60 to day +70 by flow cytometry. The P values for the t-test between the frequencies of donor cells from different treatment groups is shown.
cells by day 7 of culture ( Figure 1 ). The majority of T cells were still viable (as assessed by exclusion of propidium iodide in FACS) after 2 days of cultures following all the radiation doses tested.
Possible mechanisms of action of irradiated T cells
T cells isolated from the peripheral blood have increased levels of the nuclear transcription factor NFkB after exposure to 7.5 Gy, supporting the idea that moderate-dose radiation activated the T cells. We tested whether irradiated allo-stimulated cells retain cytotoxic activity against allogeneic targets. In order to generate cytotoxic T lymphocytes against leukemia cells, leukemia cells were irradiated (30 Gy) and co-cultured with haplo-identical PBMC at a 5:1 ratio. On day 4 exogenous IL-2 (Proleukin; Chiron, Emeryville, CA, USA) was added (10 IU/ml). Cultures were then re-stimulated weekly with irradiated leukemia in the presence of IL-2 (100 IU/ml). After 2 weeks of culture, donor T cells had significant cytotoxicity against leukemia cells, and less activity against K562, the NK cell target. The cultured donor lymphocytes retained a high degree of cytotoxicity against the stimulating leukemia cells after 3000 cGy gamma-radiation as delivered by a standard blood bank irradiator. The dose of 3000 cGy reduced maximal proliferation by 95% as measured by 3 H-thymidine incorporation.
Clinical trial using multiple infusions of irradiated allogeneic T cells to treat relapsed lymphoma and leukemia
Based upon the promising results of the pre-clinical murine studies, we initiated a phase I clinical trial of multiple infusions of irradiated allogeneic lymphocytes in patients who had relapsed after allogeneic BMT (Figure 2 ). Twelve patients have been enrolled to date with six infusions of ten million irradiated (7.5 Gy) donor T cells/kg over a 2 week period. The study population included six patients with CML in chronic phase, one patient with CML in blast crisis, three patients with NHL, and two patients with AML/MDS. No acute toxicity related to the infusions of irradiated donor lymphocytes has been seen in any patient in the current study. Patients have been followed with monthly re-staging following the last infusion of irradiated allogeneic T cells. Patients whose disease did not respond to the irradiated donor lymphocytes received one or more infusions of non-irradiated donor lymphocytes.
Of 12 patients treated to date on this study, three have shown objective responses to multiple infusions of irradiated donor lymphocytes: two patients with CML and one patient with low-grade non-Hodgkin's lymphoma. Two CML patients achieved complete cytogenetic remissions to irradiated donor lymphocytes, without any additional therapy. Five of the 12 patients have died: one patient with relapsed AML; one patient with relapsed MDS in transformation to AML; one patient with CML in blastic phase; one patient with relapsed NHL; and one patient with relapsed CML in chronic phase. Most of the early deaths occurred among patients with relapsed acute leukemia. Among the six CML treated in cytogenetic or hematological relapse on the current study, five patients remain alive, with the overall survival for this group projected to be 75%. All of the CML patients have required the administration of non-irradiated donor lymphocytes to control their CML, although one patient had a cytogenetic remission following irradiated donor lymphocytes that lasted nearly 30 months without any additional therapy. The overall survival for all 12 patients treated on this study to date is 53% (Figure 3) , with median progression-free survival of 18 months, with progression defined as either treatment with non-irradiated donor lymphocytes or death.
Clinical trial using multiple infusions of irradiated allogeneic T cells in allogeneic stem cell transplantation
The pre-clinical results from the murine studies, 14 and the preliminary clinical data presented above support further exploration of the use of irradiated allogeneic lymphocytes in stem cell transplantation. We have initiated a new phase I clinical study to test the efficacy of multiple infusions of irradiated allogeneic cytotoxic T cells to facilitate Figure 3 Overall and progression-free survival of BMT patients treated with irradiated DLI. Kaplan-Meier survival curves for patients treated on the phase I/II study of immunotherapy using irradiated donor lymphocytes. Upper curve: overall survival of all patients entered on study (n = 12) is 53%; lower curve: median progression-free survival after treatment with six infusions of irradiated allogeneic lymphocytes is 12 months. Progression-free survival is defined as patients who remain alive and free of progressive leukemia or lymphoma after receiving only irradiated donor lymphocytes.
Bone Marrow Transplantation engraftment in allogeneic transplantation. Patients with multiple myeloma are conditioned with a non-myeloablative regime consisting of melphalan and solumedrol, then transplanted with CD34 + selected allogeneic peripheral stem cells. Successive cohorts of patients will be transplanted with allogeneic stem cells alone, or a combination of allogeneic stem cells and increasing numbers of irradiated allogeneic T cells.
Discussion
Our data indicate that patients who fail to have a durable response to irradiated donor lymphocytes can be successfully salvaged using non-irradiated donor cell therapy. The clinical trial of multiple infusions of irradiated donor lymphocytes to patients relapsed after allogeneic BMT indicates this therapy is safe, well tolerated, and has anti-leukemic activity. This study also indicates the feasibility and safety of multiple infusions of irradiated donor lymphocytes into patients following allogeneic BMT. An anti-tumor response was observed in 25% of patients treated with irradiated donor lymphocytes. Irradiated allogeneic lymphocytes that retain short-term allo-specific cytotoxicity and lack the potential for clonal expansion in vivo can be considered as a novel form of immunotherapy with defined pharmacokinetics. This strategy of immunotherapy is currently being evaluated in clinical trials involving T celldepleted allogeneic hematopoietic stem cell transplants.
